Top Markets
#1 Helium Helium +47.34%
#2 TENDIES TENDIES +43.82%
#3 Pons Pons +38.81%
#4 UnifAI Network UnifAI Network +18.28%
#5 Seeker Seeker +16.90%
#6 Songbird Songbird +15.77%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +10.42%
#8 DAPPOS DAPPOS +10.15%
#9 OSK OSK +10.10%
#10 Bounce Bounce +9.81%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Hunan Jiudian Pharmaceutical Co., Ltd. Hunan Jiudian Pharmaceutical Co., Ltd.

Hunan Jiudian Pharmaceutical Co., Ltd.

300705
Rank in Stocks #10549
Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise... Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that spans the entire value chain from drug discovery and development to manufacturing and commercialization. The company's extensive product line includes medications for treating allergies, infections, and inflammatory conditions, as well as analgesics and gynecological remedies. Their offerings further extend to products for digestive health, both Western chemical drugs and traditional Chinese patent medicines, medical equipment, and Active Pharmaceutical Ingredients (APIs). Additionally, Hunan Jiudian provides contract manufacturing services for various pharmaceutical formulations, such as tablets, capsules, granules, and oral liquid preparations like solutions and syrups. The company is headquartered in Changsha, China.
Share Price
$1.64
Last synced: 2026-08-28
Market Cap
$821.42M
Change (1 day)
-1.13%
Change (1 year)
-36.82%
Country
CN
Trade Hunan Jiudian Pharmaceutical Co., Ltd. (300705)

Category

Healthcare
Revenue for Hunan Jiudian Pharmaceutical Co., Ltd. (300705)
Revenue in Aug 2026 TTM: 0
According to Hunan Jiudian Pharmaceutical Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Hunan Jiudian Pharmaceutical Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH